Sage Therapeutics (SAGE) is laying off most of its employees after announcing its planned acquisition earlier this month, The Boston Globe’s Marin Wolf reports. The company will cut 338 jobs effective August 22, according to the report. Sage announced earlier this month that it will be acquired by Supernus Pharmaceuticals (SUPN) in a deal that could be worth up to $795M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Sage Therapeutics price target raised to $9 from $7 at Baird
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist